Halozyme Therapeutics — Jan 28, 2026 release

For the full year 2026, the Company expects: • Total revenue of $1,710 million to $1,810 million, representing growth of 23% to 30% over projected 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API. • Revenue from royalties of $1,130 million to $1,170 million, representing growth of 30% to 35% over 2025. • Adjusted EBITDA of $1,125 million to $1,205 million, including new Hypercon™ and Surf Bio investment of approximately $60 million, which was not included in prior 2026 guidance. • Non-GAAP diluted earnings per share of $7.75 to $8.25. The Company’s earnings per share guidance includes new Hypercon™ and Surf Bio investment of approximately $60 million not included in prior 2026 guidance and does not consider the impact of potential future share repurchases. Table 2. 2026 Financial Guidance Previous Guidance Range New Guidance Range Expected YoY Growth 2 Total Revenue $1,430 to $1,530 million $1,710 to $1,810 million 23% to 30% Royalty Revenue $900 to $940 million $1,130 to $1,170 million 30% to 35% Adjusted EBITDA $1,000 to $1,080 million $1,125 to $1,205 million ------ Non-GAAP Diluted EPS $6.50 to $7.00 $7.75 to $8.25 ------ Footnotes: 1 Growth rates calculated from 2024 actual to low end of 2025 range and high-end of 2025 range. 2 Growth rates calculated from 2025 midpoint to low end of 2026 range and high-end of 2026 range. 3 Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See “Note Regarding Use of Non-GAAP Financial Measures” below for an explanation of these measures. 4 Including investment of approx